Study: GLP-1 Weight Loss Prescriptions Plunge 84% After Medicaid Cuts
A study published Nov. 16 in JAMA by University of Pittsburgh researchers found GLP-1 prescriptions for weight loss fell about 84% in California, New Hampshire, Pennsylvania and South Carolina after those states ended Medicaid coverage of the drugs Jan. 1, compared with 10 states that maintained coverage. Prescriptions fell from 2,914 to 421 per 100,000 Medicaid beneficiaries between late 2025 and early 2026, with Pennsylvania seeing the steepest drop at 95.5%. The authors estimated 175,500 to 526,600 fewer Medicaid beneficiaries filled these prescriptions after coverage ended, and found no significant increase in use of GLP-1s approved for diabetes in those states. The four states cited high costs for ending coverage; California had projected costs would nearly quadruple to $800 million by fiscal 2028-29. Medicaid is not required to cover weight loss drugs, unlike nearly all other outpatient drugs, and 17 state Medicaid programs have added optional coverage since 2022.